Vital Images Inc. will participate in the Image Sharing Demonstration (North Building, Hall B, booth 8140) at the annual meeting of the Radiological Society of North America (RSNA), Dec. 1-5 in Chicago.

Etiam Corp. will present the Etiam-Connect along with its Nexus 4.2 update, which features a smoother client interface, at the 2013 annual meeting of the Radiological Society of North America (RSNA).

ContextVision will debut four real-time ultrasound image enhancement packages as part of its US PlusView Family at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.

Barco, a supplier of diagnostic systems, presented its MDSC line of network-ready surgical displays.

Millar Inc. and CD Leycom announced the appointment of Millar as the exclusive U.S. distributor of CD Leycom’s clinical Inca in pressure-volume (PV) loop system and disposable clinical PV loop catheters.

ct systems angiography clinical trial study CTA 320 anio core

A 320-detector computed tomography (CT) scanner that shows both anatomy within coronary arteries and blood flow can accurately sort out which people need an invasive procedure to identify coronary blockages, according to an international study.

GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ? an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the U.S. and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the United States.

radiopharmaceuticals and tracers nuclear molecular imaging FDA lexiscan

The U.S. Food and Drug Administration (FDA) is warning healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now